SB-366791 (472981-92-3) is a potent (IC50 = 0.7 μM) and selective TRPV1 blocker.1,2 Selective for TRPV1 in a panel of 47 different binding assays.
N-(4-Methoxyphenyl)-4-chlorocinnamamide is a novel, potent, and selective cinnamide TRPV1 antagonist. Also a useful tool to further study the biology of TRPV1.
SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:
- to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
- to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
- to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)
ChEBI: 3-(4-chlorophenyl)-N-(3-methoxyphenyl)-2-propenamide is a member of cinnamamides and a secondary carboxamide.
Potent, selective and competitive vanilloid TRPV1 (VR1) receptor antagonist (pA 2 = 7.71 at hVR1); antagonizes hTRPV1 receptors activated by agonists, noxious heat, but not protons. Displays selectivity over a wide range of receptors and systems including CB 1 and CB 2 receptors, voltage-gated Ca 2+ channels and the hyperpolarization-activated current (I h ). Also available as part of the Vanilloid TRPV1 Receptor Tocriset™ .
SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
[1] M.J. GUNTHORPE . Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist[J]. Neuropharmacology, 2004, 46 1: Pages 133-149. DOI:
10.1016/s0028-3908(03)00305-8[2] ANGELIKA VARGA . Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat[J]. Neuroscience Letters, 2005, 385 2: Pages 137-142. DOI:
10.1016/j.neulet.2005.05.015
